Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …
Cancer immune evasion through loss of MHC class I antigen presentation
K Dhatchinamoorthy, JD Colbert, KL Rock - Frontiers in immunology, 2021 - frontiersin.org
Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …
expressed genes and then transport and display this antigenic information on the cell …
Cancer Immunoediting in the Era of Immuno-oncology
Basic science breakthroughs in T-cell biology and immune–tumor cell interactions ushered
in a new era of cancer immunotherapy. Twenty years ago, cancer immunoediting was …
in a new era of cancer immunotherapy. Twenty years ago, cancer immunoediting was …
Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma
Y Li, J Gu, F Xu, Q Zhu, Y Chen, D Ge… - Briefings in …, 2021 - academic.oup.com
Abstract N6-methyladenosine (m6A) modification can regulate a variety of biological
processes. However, the implications of m6A modification in lung adenocarcinoma (LUAD) …
processes. However, the implications of m6A modification in lung adenocarcinoma (LUAD) …
[HTML][HTML] Rethinking immune checkpoint blockade:'Beyond the T cell'
X Liu, GD Hogg, DG DeNardo - Journal for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
The clinical success of immune checkpoint inhibitors has highlighted the central role of the
immune system in cancer control. Immune checkpoint inhibitors can reinvigorate anti-cancer …
immune system in cancer control. Immune checkpoint inhibitors can reinvigorate anti-cancer …
Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis
The immunosuppressive microenvironment that is shaped by hepatic metastatic pancreatic
ductal adenocarcinoma (PDAC) is essential for tumor cell evasion of immune destruction …
ductal adenocarcinoma (PDAC) is essential for tumor cell evasion of immune destruction …
Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDA) orchestrates a suppressive tumor
microenvironment that fosters immunotherapy resistance. Tumor-associated macrophages …
microenvironment that fosters immunotherapy resistance. Tumor-associated macrophages …
Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy
Response to immunotherapy widely varies among cancer patients and identification of
parameters associating with favourable outcome is of great interest. Here we show …
parameters associating with favourable outcome is of great interest. Here we show …
Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
HB Li, ZH Yang, QQ Guo - Cell Communication and Signaling, 2021 - Springer
Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate
among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common …
among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common …
Modeling pancreatic cancer in mice for experimental therapeutics
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy that is
characterized by early metastasis, low resectability, high recurrence, and therapy resistance …
characterized by early metastasis, low resectability, high recurrence, and therapy resistance …